References
- Overdose Death Rates | National Institute on Drug Abuse (NIDA); 2018; [cited 2019 Jan 1]. Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates
- Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf. 2015;14:1137–1146.
- Wilkerson RG, Kim HK, Windsor TA, et al. The opioid epidemic in the United States. Emerg Med Clin North Am. 2016;34:e1–e23.
- Rudd RA, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths – United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–1452.
- Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372:241–248.
- Lucyk SN, Nelson LS. Toxicosurveillance in the US opioid epidemic. Int J Drug Policy. 2017;46:168–171.
- Lucyk SN, Nelson LS. Novel synthetic opioids: an opioid epidemic within an opioid epidemic. Ann Emerg Med. 2017;69:91–93.
- Centers for Disease Control and Prevention (CDC). Nonpharmaceutical fentanyl-related deaths – multiple states, April 2005–March 2007. MMWR Morb Mortal Wkly Rep. 2008;57:793–796.
- U.S. Drug Enforcement Administration. National Forensic Laboratory Information System Brief: fentanyl, 2001–2015. Springfield, VA; 2017; [cited 2019 Jan 1]. Available from: https://www.nflis
- Gladden RM, Martinez P, Seth P. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths – 27 states, 2013‒2014. MMWR Morb Mortal Wkly Rep. 2016;65:837–843.
- Peterson AB, Gladden RM, Delcher C, et al. Increases in fentanyl-related overdose deaths – Florida and Ohio, 2013–2015. MMWR Morb Mortal Wkly Rep. 2016;65:844–849.
- U.S. Drug Enforcement Administration. DEA issues nationwide alert on fentanyl as threat to health and public safety; 2015; [cited 2019 Jan 1]. Available from: https://www.dea.gov/press-releases/2015/03/18/dea-issues-nationwide-alert-fentanyl-threat-health-and-public-safety
- Griswold MK, Chai PR, Krotulski AJ, et al. Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose. Clin Toxicol (Phila). 2018;56:37–42.
- FDA Advisory Committee on the most appropriate dose or doses of naloxone to reverse the effects of life-threatening opioid overdose in the community settings; 2 September 2016. Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee; 2016; [cited 2019 Jan 1]. Available from: https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anestheticandanalgesicdrugproductsadvisorycommittee/ucm522688.pdf
- Zuckerman M, Weisberg SN, Boyer EW. Pitfalls of intranasal naloxone. Prehosp Emerg Care. 2014;18:550–554.
- Gufford B, Ainslie G, White J, et al. Comparison of a new intranasal naloxone formulation to intramuscular naloxone: results from hypothesis-generating small clinical studies. Clin Transl Sci. 2017;10:380–386.
- Klebacher R, Harris MI, Ariyaprakai N, et al. Incidence of naloxone redosing in the age of the new opioid epidemic. Prehosp Emerg Care. 2017;21:682–687.
- Wheeler E, Jones TS, Gilbert MK, et al. Centers for Disease Control and Prevention (CDC). Opioid overdose prevention programs providing naloxone to laypersons – United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:631‒635.
- Faul M, Lurie P, Kinsman JM, et al. Multiple naloxone administrations among emergency medical service providers is increasing. Prehosp Emerg Care. 2017;21:411–419.
- Bell A, Bennett AS, Jones TS, et al. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply. Subst Abus. 2018 Mar 20:1–4. doi: 10.1080/08897077.2018.1449053 [Epub ahead of print].
- DEA Intelligence BRIEF: fentanyl remains the most significant synthetic opioid threat and poses the greatest threat to the opioid user market in the United States; 2018; [cited 2019 Jan 1]. Available from: https://ndews.umd.edu/sites/ndews.umd.edu/files/fentanyl-remains-most-significant-synthetic-opioid-threat-2018.pdf
- Unintentional drug- and alcohol-related intoxication deaths in Maryland, annual report 2017 | Maryland Department of Health; 2018; [cited 2019 Mar 7]. Available from: https://bha.health.maryland.gov/OVERDOSE_PREVENTION/Documents/Drug_Intox_Report_2017.pdf
- Amlani A, McKee G, Khamis N, et al. Why the FUSS (fentanyl urine screen study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduct J. 2015;12:54.
- Dowling J, Isbister GK, Kirkpatrick CMJ, et al. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008;30:490‒496.
- Mundin G, McDonald R, Smith K, et al. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. Addiction. 2017;112:1647–1652.
- Vanky E, Hellmundt L, Bondesson U, et al. Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. Acta Anaesthesiol Scand. 2017;61:636–640.
- Tylleskar I, Skulberg AK, Nilsen T, et al. Pharmacokinetics of a new, nasal formulation of naloxone. Eur J Clin Pharmacol. 2017;73:555–562.
- Krieter P, Chiang N, Gyaw S, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 2016;56:1243–1253.
- Ryan SA, Dunne RB. Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review. Pain Manag. 2018;8:231–245.